newsfilter
← Earnings
Earnings Releases·

LENZ Therapeutics — Third Quarter 2026 Earnings Summary

  • Total revenue declined to $3.4 million in Q3 2026 from $12.5 million in the prior year period, driven by a drop in license revenue to $0.8 million, while product sales grew to $2.6 million from zero; net loss widened to $31.0 million ($0.99 per share) compared to $16.7 million in Q3 2025.
  • The company expects to reduce 2027 annual operating expenses by over 50% to a range of $70 million–$75 million (excluding stock-based compensation) following a strategic reorganization expected to incur approximately $5 million in one-time restructuring charges completed in Q4 2026.
  • VIZZ commercial momentum accelerated with Q3 2026 sales representing over 38,000 prescriptions (a 51% increase over Q2), where the telehealth option contributed more than 50% of incremental volume, supported by a nationwide TV campaign and international regulatory filings in Saudi Arabia, Malaysia, and Vietnam.
  • Leadership transitioned effective December 1, 2026, with outgoing CEO Eef Schimmelpennink moving to a strategic advisor role and incoming Interim CEO Dan Chevallard assuming the presidency to execute a focused commercial strategy.
Company
LENZ THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology